Table-I: Represents demographics and biochemical parameters of T1DM,
T2DM and control subjects.
Approximately 24 million
T2DM patients in Europe are likely to develop diabetic kidney disease (DKD),2 which is projected to rise in line with the increasing prevalence of diabetes.
Approximately 24 m
T2DM patients in Europe are likely to develop diabetic kidney disease,2 which is projected to rise in line with the increasing prevalence of diabetes.
Eun-Ok Im, Ph.D., from Duke University in Durham, North Carolina, and colleagues used data from 164 participants of two larger internet survey studies (62 women diagnosed with
T2DM and 102 women without diabetes) to evaluate associations between
T2DM and sleep-related symptoms among midlife women.
JPAD 2 was the first-ever study to evaluate the long-term efficacy of low-dose aspirin for prevention of dementia specifically in patients with
T2DM, a known risk factor for dementia.
[7] HbA1c of 7% is the suggested glycaemic target for
T2DM patients.
24 SGLT-2 inhibitors have been used in both the initiation and intensification of therapy of
T2DM. The approved drugs in this class include dapagliflozin (2012), canagliflozin (2013), empagliflozin (2014), and ertugliflozin (2017).
(2,3) The treatment of
T2DM is generally multimodal in order to target the various mechanisms that cause hyperglycemia.
Recent studies have shown the positive effects of bariatric surgery procedures in the treatment of obese and non-obese patients with
T2DM. Therefore, bariatric surgery is also referred to as metabolic surgery due to its effects ranging from weight loss to metabolic control, especially in patients with
T2DM.
This study stresses on the collaborative work to manage
T2DM especially in patients with uncontrolled blood sugar.
Exercise is considered as the main building block of
T2DM treatment (2).
The medications, which include sitagliptin (Januvia) and linagliptin (Tradjenta), are used to treat patients with
T2DM who are inadequately controlled by first-line treatments.